Quintiles Library

Embrace Value-based Healthcare
Featured White Paper

Value to outcomes (V2O)
Life Science companies that stand to thrive in the increasingly evidence-based marketplace will be those who embrace value-based healthcare and catalyze the system movement toward enhanced outcomes. By understanding the interdependent trends, firms can drive improvements in population health outcomes while navigating these transformational changes....
Show Filters
Press Release
RESEARCH TRIANGLE PARK, N.C. – March 25, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to Forbes magazine’s first-ever “America’s Best Employers” list as rated by more than 20,000 independent survey responses. Quintiles is ranked as the 30th best employer in the United States and comes in third in the “Drugs and Biotechnology” category. In all, 500 companies are included in the 2015 Forbes list. “Being named one of the top employers in the U.S. is a great honor for Quintiles and says a lot about our values, our people and company mission,” said Chief Human Resources Officer Garrett Walker. “Our organization is committed to building and sustaining a work environment that enables our talent to be high performing, successful in achieving their...
Read More
Fact Sheet
ワクチンの臨床開発:インフォグラフィック クインタイルズの臨床試験、そのリソースやグローバルなセントラルラボが2013年度の上位35のワクチン製品/化合物の開発・上市に役立ってます。詳細はリンク先をご覧ください。コンテンツは日本語です。
Read More
Fact Sheet
オンコロジーの臨床開発:インフォグラフィック...
Read More
Press Release
SINGAPORE – March 25, 2015 – Quintiles Head of Asia Markets Anand Tharmaratnam, M.D., last night was honored as “Best Life Science Asian Male Executive of the Year” at the BioPharma Asia Industry Awards.  Dr. Tharmaratnam was selected in a vote of biopharmaceutical industry professionals from five distinguished executives shortlisted for the award. “On behalf of the hundreds of voters who made their voices heard in the competition, we are pleased to present this award to Dr. Tharmaratnam,” said Sharon Roessen, Managing Director of Terrapinn Pte Ltd, organizer of BioPharma Asia Convention 2015.  “His visionary leadership and Quintiles’ stellar work were frequent themes in voter comments. We would like to thank Anand for his contributions to advancing Asia’s biopharma industry.” Over the...
Read More
Brochure
The oncology environment is rapidly changing, and the integration of real world research throughout the product lifecycle is becoming increasingly critical to product development and commercialization. Quintiles’ integrated approach to real-world and late phase oncology research is designed to facilitate your success and bring better treatments to patients...
Read More
Fact Sheet
Quintiles’ HTA Watch is a web-based service offering instant access to a global repository of published HTA reports from nearly 100 agencies in 32 countries, providing regularly updated assessments to help inform life sciences and healthcare companies’ strategic decision-making*.  In this edition of our HTA uncovered series, we'll explore Real world evidence and collecting the right data to satisfy multiple stakeholder needs plus payers’ perspectives on endpoints in oncology trials. Click here for the March edition * Any assessments or evaluations are provided by Quintiles as a service for information purposes only, and are based on the HTA reports referenced...
Read More
Expert
The Cardiac Safety arena is evolving and regulators are considering issuing modified requirements to allow cardiac safety testing to be conducted earlier in the development process. In this article, Quintiles cardiac safety experts provide the historic context for cardiac safety testing and options for moving...
Read More
White Paper
Strategies for dose escalation during first-in-human studies are critical for volunteer safety and for study success. Decisions regarding dose escalation involve balancing three elements: risks to individual volunteers; risks of failing to identify the correct dose range to use in subsequent studies; and risks of delaying or stopping development of a potentially useful product. Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation offer a set of tools to increase the predictability of drug candidate performance. By identifying the best individualized dosing regimen to treat a given indication, patient outcomes can be improved, and the probability of a molecule’s success can be increased. Authors: Professor Tim Mant, FRCP FFPM, Vice President, Medical Research and Principal...
Explore More
Expert
As increasing numbers of highly-successful biologics come off patent, biosimilars are a promising area for investment, offering growth potential that is lacking in many other areas of the biopharma market. This two-part series examines the environment for third-party capital providers. Part 1 provides an introduction to this complex area, describing key players entering the biosimilars market, ongoing biosimilar trials and the rationale behind partnering. It then examines three hurdles that must be addressed: manufacturing, immunogenicity and data generation (from pharmacokinetic/pharmacodynamic studies and clinical trials). Part 2 describes three additional hurdles: access to capital, exclusivity and intellectual property, and...
Read More
White Paper
Value-based medicine is giving patients more power as consumers of healthcare products -- and the industry must respond. A recurring theme at EVF, experts and speakers returned repeatedly to the notion of the patient as consumer, and what payers, pharma, providers and practitioners must do to accommodate this increasingly powerful stakeholder...
Explore More
Brochure
By blending specialized scientific and operational expertise with innovative technology, Quintiles can help determine the right research questions, then develop the best study designs and implement them efficiently to support your cardiovascular portfolio evidence...
Read More
Expert
Medical outcome trials--large-scale, long-duration clinical trials with hard endpoints, including morbidity and mortality-can answer critical questions about product safety and efficacy and are among the most expensive and logistically challenging trials in the entire product life cycle. They can show long-term safety in therapies for chronic diseases such as type 2 diabetes, rheumatoid arthritis, osteoarthritis, and asthma, and efficacy in those for cardiovascular...
Read More
Brochure
Health Engagement & Communications is an agency positioned at the forefront of innovation and is part of Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services. Immersed in healthcare, we build engaging, innovative experiences for patients and healthcare professionals to drive meaningful change and improve outcomes. Quintiles has been involved in the development or commercialization of all of the top 100 best-selling products or compounds of 2013. The breadth of experience that we can draw upon to design and deliver engagement and communication solutions is unmatched in the...
Read More
Expert
Biologics are truly innovative therapies, but they are extremely expensive. The development of biosimilar medicines is an emerging field that is generating high levels of interest within industry, and offers the prospect of increasing patient access to these highly effective medicines. Currently, the global biosimilars market includes monoclonal antibody (mAb) biosimilars for the treatment of cancer and autoimmune conditions (e.g., rheumatoid arthritis), as well as insulins, interferons, erythropoietin, filgrastim, somatropin and follicle stimulating hormone. Of these, the mAb and insulin markets are forecast to record the highest growth rates, with these two segments representing a projected 46% of the global biosimilars market by 2018, by which time many leading brands will have lost...
Read More
Brochure
より良い結果のために早期臨床開発を変革:冊子 人材や財源への投資拡大。臨床試験デザインの複雑化。患者を対象にした医薬品試験の早期化。これらは全て早期臨床開発における最近の動向であり、課題ではありますが、開発プロセスをより効率的で統合されたものに改善させ、投資利益を大幅に増加させる推進力をもたらします。クインタイルズには様々な治療領域における早期臨床開発で30年以上の経験があります。変革的な早期開発アプローチのパイオニアとして、クインタイルズでは実施/中止判断の的確化と迅速化、治験の進行を安全に加速、後期相の成功に向けて基盤を構築でお客様をサポートします。...
Read More
Expert
Biopharmaceutical companies’ commercial models must respond to an ever-changing marketplace, with increasing demands from both payers and patients for better care, improved outcomes, more affordable therapies, and increased speed to market. In a recent interview, George Esgro, Vice President & Head, U.S. Commercial Solutions, Quintiles, discussed how strategic outsourcing can help companies deliver the necessary adaptability, flexibility and cost...
Read More
Fact Sheet
The vast nature of phenotypes across asthma – COPD, IPF and others – is just one of the many challenges in managing early phase respiratory clinical research. Specialized equipment, facilities, medical and scientific expertise are required to gain the best possible data from these early...
Read More